Incidence And Clinical Implications Of A New Definition Of Hyperprogression (Hpd) With Immune Checkpoint Inhibitors (Icis) In Patients Treated In Phase 1 (Ph1) Trials.

3032Background: HPD with ICIs has been recently described as progression disease (PD) by RECIST with a ≥ two-fold increase in tumor growth rate experimental vs. reference. However, the implementation of such assessment is challenging and its clinical implications have not been clearly established. Methods: Patients (pts) treated with ICIs in Ph1 trials at Vall d´Hebron Institute Oncology (VHIO) were analysed (n = 214). We defined HPD based on RECIST 1.1 as time to treatment failure (TTF) u003c 2 months (m) and minimum increase in measurable lesions of 10 mm plus: 1) increase of ≥40% (upper decile of our cohort) in target tumor burden compared to baseline or 2) increase of ≥20% plus the appearance of multiple new lesions. The aim of this study was to correlate HPD with overall survival (OS) in pts who achieved PD as best response, by using a Kaplan-Meier analysis. Results: From Jan’12 to Oct’17, 214 pts were treated, mostly with antiPD1/PDL1 ICIs (53% in combinations with other ICI). Median age 58y (20-85). Tu...